Centessa Pharmaceuticals (CNTA) Common Equity (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Common Equity data on file, last reported at $487.3 million in Q1 2026.

• Quarterly Common Equity rose 26.18% year-over-year to $487.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $487.3 million (up 26.18% YoY) and the FY2025 annual result came in at $526.9 million, up 31.21% from the prior year.
• Common Equity eased to $487.3 million in Q1 2026 per CNTA's latest filing, from $526.9 million in the prior quarter.
• Across five years, Common Equity topped out at $526.9 million in Q4 2025 and bottomed at $215.2 million in Q1 2024.
• The 5-year median for Common Equity is $344.9 million (2025), against an average of $360.3 million.
• The widest annual swing landed in 2024, when Common Equity soared 92.43%; it then tumbled 39.58% in 2025.
• Tracing CNTA's Common Equity over 5 years: stood at $336.2 million in 2022, then declined by 29.72% to $236.2 million in 2023, then surged by 69.97% to $401.5 million in 2024, then jumped by 31.21% to $526.9 million in 2025, then declined by 7.5% to $487.3 million in 2026.
• Per Business Quant, the three latest CNTA Common Equity figures stand at $487.3 million (Q1 2026), $526.9 million (Q4 2025), and $301.6 million (Q3 2025).

Peer Comparison